The announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis ...

A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...

But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show if twice daily oral dosing of ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...

PTC Therapeutics' Phase II trial for utreloxastat in ALS failed to meet its primary endpoint, showing no significant ...

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

PTC Therapeutics said on Tuesday its drug did not meet the main goal in a mid-stage trial evaluating it in patients with a type of fatal neurodegenerative disease called amyotrophic lateral sclerosis.

PTC Therapeutics will scrap development of its treatment for amyotrophic lateral sclerosis after it failed to meet a primary endpoint in a Phase 2 trial.

A biotech start-up that has shown the ability to pause and in some cases reverse neurodegenerative diseases in mice has ...

While speaking during a conference, Giancarlo Comi suffered a sudden illness. The Italian luminary of neurology has died. He ...

PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including ...

At Lenovo Tech World '24, global technology leader Lenovo and the Scott-Morgan Foundation (SMF), a non-profit pioneering innovative assistive tech, revealed an AI-powered solution for people with ...